Exicure Agrees to Sell Cancer Drug Assets for $4.8 Million
WILMINGTON, DE — Exicure Inc. (Nasdaq: XCUR) has agreed to sell its GPC-100 cancer drug development assets to South Korea-based GPCRT Inc. for approximately $4.8 million, a transaction intended to …
Exicure Agrees to Sell Cancer Drug Assets for $4.8 Million Read More